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Abstract (275/275 words) 
 
Background 
There is limited guidance for using common drug therapies in the context of multimorbidity. 
In part, this is because their effectiveness for patients with specific comorbidities cannot 
easily be established using subgroup analyses in clinical trials. Here, we use simulations to 
explore the feasibility and implications of concurrently estimating effects of related drug 
treatments in patients with multimorbidity by partially pooling subgroup efficacy estimates 
across trials. 
Methods 
We performed simulations based on the characteristics of 161 real clinical trials of non-
insulin glucose lowering drugs for diabetes, estimating subgroup effects for patients with a 
hypothetical comorbidity across related trials in different scenarios using Bayesian 
hierarchical generalised linear models. We structured models according to an established 
ontology – the World Health Organisation Anatomic Chemical Therapeutic Classifications 
(WHO-ATC) – allowing us to nest all trials within drugs and all drugs within ATC classes, 
with effects partially pooled at each level of the hierarchy. In a range of scenarios, we 
compared the performance of this model to random effects meta-analyses of all drugs 
individually. 
Results 
Hierarchical, ontology-based Bayesian models were unbiased and accurately recovered 
simulated comorbidity-drug interactions. Compared to single drug meta-analyses, they 
offered a relative increase in precision of up to 250% in some scenarios due to information 
sharing across the hierarchy. Due to the relative precision of the approaches, a high 
proportion of small subgroup effects were only detectable using the hierarchical model. 
Conclusions 
By assuming that similar drugs may have similar subgroup effects, Bayesian hierarchical 
models based on structures defined by existing ontologies can be used to improve the 
precision of treatment efficacy estimates in patients with multimorbidity – with potential 
implications for clinical decision-making. 
 
Keywords 
Subgroup analysis; individual-patient data meta-analysis; multimorbidity; hierarchical 
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Multimorbidity, which is defined as the presence of two or more chronic conditions within an 
individual, is common and increasing. More than half of patients with any chronic disease 
have multimorbidity.(1) This represents a challenge because the applicability of clinical trial 
results to patients with multimorbidity is uncertain. Consequently, several clinical guideline 
bodies have urged caution in applying trial results to patients with multimorbidity,(2) while in 
practice patients with multimorbidity are less likely to receive drug-treatments shown to be 
effective in clinical trials, even where there is no contraindication to therapy.(3–6)  
 
One reason for this uncertainty is that multimorbidity is under-represented in clinical 
trials.(7,8)  For this reason, some researchers have used observational data – particularly 
administrative data, in which multimorbidity is common – to estimate treatment effects. 
However, such “pharmaco-epidemiological” approaches are subject to confounding by 
indication (9) despite methodological advances, (10,11) and so remain restricted in terms of 
their utility to support medical decision making in this regard. 
 
Moreover, while multimorbidity may not be present at the same rate in clinical trials 
compared to in the community, it is nonetheless common. For half of 22 medical conditions, 
we found that at least a third of trial participants – in standard industry-funded clinical trials – 
had multimorbidity. Furthermore, similar comorbidities were common in the trial and 
community settings.(8) Consequently, there is both a need and an opportunity to determine 
whether treatment effects in clinical trials differ for sub-groups of patients with and without 
multimorbidity, and for different patterns of multimorbidity.  
 
Reliably estimating treatment effects for sub-groups in individual clinical trials is notoriously 
difficult.(12–14) Claims of sub-group effects made in clinical trial reports are frequently 
unsupported by appropriate statistical evidence (15). While pre-specified sub-group analyses 
can be adequately powered, there are often insufficient numbers of participants to estimate 
differences in effects across sub-groups (especially for specific comorbidities) with adequate 
precision to inform clinical decision-making.(13) Moreover, simple methods to reduce the 
risk of false positives (i.e., by asserting that there is heterogeneity when none exists) do so at 
the expense of precision and increase in Type 2 errors.(16) Consequently, attempts to 
estimate treatment effects for patients with multimorbidity are likely to suffer from both poor 
sensitivity and poor specificity. 
 
Meta-analyses pool findings across trials to improve precision,(17) and individual patient 
data (IPD) meta-analyses can be used to pool treatment effect estimates for participants with 
specific characteristics such as particular comorbidities.(18) Even for meta-analyses, 
however, estimating sub-group effects with sufficient precision to inform clinical decision 
making is challenging because, compared to the overall trial, data on particular sub-groups 
can be limited. 
 
One approach to dealing with limited data is to use hierarchical modelling.(19) Within a 
Bayesian framework, hierarchical modelling is straightforward,(20) and has previously been 
shown to be useful for analysing clinical trial data. Examples include performing subgroup 
analyses,(19) and estimating adverse treatment effects.(21) Such approaches rely on the 
assumption that information can be shared between parameters. In an information-sharing 
approach to sub-group analysis, Dixon and Simon(20) assumed that treatment-covariate 
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interactions came from a common prior distribution. Similarly, in estimating effects of 
treatments on adverse events, Berry and Berry(21) assumed that events occurring within 
specific body systems (e.g., the gastrointestinal system) were related. In both examples, 
separate estimates were “partially pooled”, increasing precision and attenuating extreme 
values towards the group-level mean (shrinkage). Partial pooling and shrinkage are 
established features of hierarchical models.(22) These are desirable features for subgroup 
analyses as, where the assumption that information can be shared holds, they are likely to 
improve our ability to detect true subgroup effects, while reducing false positives. 
 
Despite these desirable properties, the use of hierarchical modelling in subgroup analyses has 
thus far has been limited. One reason for the limited adoption may be uncertainty in how to 
allow sharing of information between different trials – that is, how should hierarchical 
models be structured. Using established drug-related ontologies such as the World Health 
Organisation Anatomic Chemical Therapeutic Classifications (WHO ATC), which is a tree-
like classification scheme based on therapeutic indications and chemical forms,(23) and 
MED-RT, a US-based ontology which provides finer granularity for mechanisms of 
action,(24) may help overcome this barrier. Such ontologies represent expert knowledge 
about similarities, differences, and relationships between different drugs in terms of 
indications, chemical structures, and other features, providing a starting point from which to 
define a hierarchical structure for modelling. 
 
In other fields, relationships within ontologies have been used to predict protein–protein 
interactions, diagnoses and the classification of chemicals.(25) Ontologies have also been 
exploited to support the management and execution of clinical trials.(26–29) Since WHO-
ATC, MED-RT and other ontologies are publicly available, they provide a transparent 
starting point for analyses. This aspect of ontologies is appealing in the field of clinical trial 
meta-analysis where transparency, consistency and pre-specification are highly prized.(30)  
The current study 
In this study, we address the question of whether partial-pooling of subgroup effects in 
existing clinical trial data – using structures borrowed from established drug classification 
ontologies – is feasible and has the potential to support clinical decision making. To do this, 
we first simulate datasets with interactions between a group of non-insulin glucose lowering 
drugs for diabetes and a single hypothetical comorbidity, based on the characteristics of real 
trials. Next, we apply Bayesian hierarchical generalized linear models, with individual trials 
nested within drugs nested within ATC drug classes, to these data. Our use of an established 
ontology to structure a hierarchical meta-analysis is based on the simple assumption that 
drugs that are similar may behave similarly in subgroups. We compare the performance of 
these ontology-based hierarchical models, in terms of their recovery of comorbidity-treatment 
interaction effects for individual drugs, with that of standard, single-drug meta-analyses (see 
Figure 1 for an overview). In addition, we highlight specific properties of these models that 
emphasize their potential utility in IPD meta-analyses of comorbidity-based sub-group effects 
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Identification and classification of existing trials as basis for simulation 
We opted to base our simulations on the characteristics of real trials of an exemplar drug 
grouping: non-insulin glucose lowering drugs for diabetes. We identified all relevant existing 
trials on the US clinical trials register (clinicaltrials.gov) that met a set of pre-specified 
selection criteria [Prospero protocol CRD42018048202 (31)]. Briefly, these included a 
minimum enrolment of 300 participants, a start date of 1 January 1990 or later, being a phase 
2/3, 3, or 4 trial, and having an upper age limit of 60 years or more. We used trial-level 
descriptive information that is publicly available on their clinicaltrials.gov record trials to 
define the structure of the simulated data to reflect, as closely as possible, the characteristics 
of real IPD that is (theoretically) available from trial sponsors. Specifically, we obtained 
information about the number of trials available per drug and class, and the number of 
participants enrolled in each trial, and used these characteristics as the basis of our 
simulations of subgroup effects for each trial. For simplicity, all trials were treated as single-
arm versus placebo/usual care in the simulation. 
 
After classification according to the WHO-ATC ontology, we included 161 trials involving  
210,046 participants, of 24 separate drugs from 7 different WHO-ATC 5-level classes (e.g., 
DPP-4 inhibitors, SGLT-2 inhibitors). Full details of the classifications are provided in 
sAppendix 1 and sTable 1.  
Data generation procedure 
We simulated data to generate trial-level subgroup effects for each of the 161 trials. This was 
to reflect a situation where individual patient level data for these trials had been shared, and 
the effect of an interaction between a particular comorbidity and the drug treatment under 
investigation had been estimated for each trial in preparation for meta-analysis – which is a 
common analytical approach in IPD meta-analysis. (17)  
 
Data were simulated based on an overall comorbidity-treatment interaction of -0.1 standard 
deviations at the level of the wider drug grouping (i.e., the top level of the hierarchy, 
reflecting the average interaction effect across all drugs). This was chosen as a minimum 
difference which might plausibly be important for decision-making, recognising that sub-
group interactions are likely to be modest in real applications. This effect size would mean 
that, for a treatment minus control arm difference in efficacy of 0.2 standard deviations, the 
treatment efficacy in patients with multimorbidity would be 0.1 standard deviations. 
 
Trial-level effects were simulated by adding random variation around the overall 
comorbidity-treatment interaction effect at each level of the hierarchy (i.e., at the level of 
drug class, drug, and trial). We simulated 1000 datasets for each of a range of scenarios, 
reflecting different degrees of between-trial, between-drug, and between-class variability: 
 
All levels: low variation 
In this scenario, we simulated 1000 datasets with trial-level interaction effects by adding 
random variation of 0.05 SDs at the levels of drug class, drug, and trial to the fixed overall 
effect of -0.10 SDs. Datasets in this scenario represent situations where all trials of a given 
drug, all drugs in a given class, and all classes of drugs in the hierarchy have highly similar 
estimates for a given comorbidity-treatment interaction effect. 
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All levels: medium variation 
In this scenario, we simulated 1000 datasets with trial-level interaction effects by adding 
random variation of 0.15 SDs at the level of drug class, drug, and trial to the fixed overall 
effect of -0.1 standard deviations. Datasets in this scenario represent situations where all trials 
of a given drug, all drugs in a given class, and all classes of drugs in the hierarchy have 
moderately similar estimates for a given comorbidity-treatment interaction effect. 
 
All levels: high variation 
In this scenario, we simulated 1000 datasets with trial-level interaction effects by adding 
random variation of 0.25 SDs at the level of drug class, drug, and trial to the fixed overall 
effect of -0.1 standard deviations. Datasets in this scenario represent situations where all trials 
of a given drug, all drugs in a given class, and all classes of drugs in the hierarchy have 
relatively dissimilar estimates for a given comorbidity-treatment interaction effect. 
 
Other scenarios: variation manipulated at a specific level of the hierarchy 
We additionally simulated sets of 1000 datasets in scenarios where, during the data 
generation procedure, we manipulated variation at each level of the hierarchy in turn, while 
keeping variation at the other levels constant at 0.05 SDs. So, for example, this allowed us to 
represent situations where trial-level estimates of comorbidity-treatment interactions for a 
given drug were highly dissimilar, but drugs and drug classes behaved more consistently (i.e., 
a “Trial-level: high variation” scenario, where trial-level interaction effects were simulated by 
adding random variation of 0.05 SDs at the level of drug class and drug, but 0.25 SDs at the 
level of trial, to the fixed overall effect of -0.1 standard deviations.) 
 
In the main analyses, we assumed the prevalence of the comorbidity that defines the 
subgroup to be 20%. This value is used in determining the precision of the simulated trial-
level interaction estimate, which is also based on the number of individuals enrolled in the 
trial and is the same across datasets and scenarios. Further details of the simulation procedure 
are given in sAppendix 2 and an abbreviated example of a simulated dataset is presented in 
sTable 2. 
Modelling  
To each simulated dataset, we fitted: i) a hierarchical generalized linear model with all trials 
nested within drugs, nested within ATC-5 drug classes (henceforth “the full model”); and ii) 
hierarchical generalized linear models for all trials of each of the 24 drugs (henceforth 
“single-drug models”). We fit these models using the R-INLA package.(32) Although 
integrated nested Laplacian approximation (INLA) performs approximate Bayesian 
inference, and offers less flexibility than software which uses Markov-chain Monte Carlo 
(MCMC) methods to fit models (specifically, hyperpriors must be Gaussian – an acceptable 
restriction in this case), model-fitting using R-INLA is very rapid, and gave good agreement 
to MCMC. Using R-INLA meant we could run the models on a larger number of simulated 
iterations and scenarios.  
Full model description 
Interactions at the various levels of the hierarchy were specified as follows: 
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Trial-specific comorbidity-treatment interactions 
!!,#,$ ∼ #(%!,#,$ , '!,#,$% ) 
Between-trial variation in comorbidity-treatment interactions 
%!,#,$ ∼ #()#,$ , *#,$% ) 
Between-drug variation in comorbidity-treatment interaction 
)#,$ ∼ #(+$ , ,$%) 
Between-class comorbidity-treatment interaction 
+$ ∼ #(-, .%) 
 
The observed quantities y	and s represent the comorbidity-treatment interaction and standard 
error at the level of the individual trial. Normal distributions are parameterised as mean and 
variance. The / subscript indicates the trial, the 0 subscript indicates the drug, and the 1 
subscript indicates the drug class. The prior for the overall mean comorbidity-treatment 
interaction - was a Normal distribution [#(0, 2%)]. This was chosen to correspond to the 
assumption that covariate treatment interactions are uncommon (when trial data are analysed 
on an appropriate scale). For the between drug class variation	. , the between-drug (i.e., 
within-class) variation (,$)  and the between-trial (i.e., within-drug) variation (*#,$)  we used 
half-Normal priors on the standard deviations:	ℎ678#(0, 1%) . The priors were selected to be 
relatively non-informative in relation to the values for variance at these levels used during the 
data generation (0.052, 0.152, 0.252), in order to ensure that the performance of the full model 
was not artificially aided by our knowledge of these values.  
 
Single-drug models were specified using the lowest two levels of the full model (i.e., trial-
specific and between-trial) as outlined above, and with the prior for the mean comorbidity-
treatment interaction for a given drug )#,$ parameterized as a Normal distribution [#(0, 2%)]. 
Performance evaluation and sensitivity testing 
We evaluated the performance of the full model against that of the single drug models on 
their recovery of the drug-level interaction effect. In accordance with the framework outlined 
by Morris et al (33), we compare the two approaches on several established performance 
measures: bias (the extent to which the effect is systematically over-/underestimated); mean 
squared error (MSE; the average extent to which the effect is over or underestimated) and 
root mean squared error (RMSE; equivalent to MSE but interpretable on the same scale as the 
data); change in precision relative to the single drug model; and coverage (the proportion of 
credible intervals containing the true value). We used the R package rsimsum (34)to derive 
estimates and Monte Carlo standard errors for each of the measures (RMSE was derived 
manually and standard errors approximated using the delta method). 
 
To evaluate the sensitivity of the models to the prevalence of the subgroup-defining 
comorbidity, we re-ran all analyses with this value set at 10 and 50% respectively. 
 
The R code for the simulation and modelling are available at 
https://github.com/dmcalli2/simlt_interactions/blob/master/scripts/.  
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The relative performance of the full and single drug models is summarized in Table 1. 
Performance measures are aggregated across datasets and scenarios according to amount of 
variability around the overall average interaction effect of -0.1 that was introduced at each 
level of the hierarchy during data generation, as described in the Data generation procedure 
section above. As such, the top section of the table shows results for all datasets in three main 
scenarios: “All levels: low variation”, “All levels: medium variation”, “All levels: high 
variation”. In the lower section of the table, results are summarized for scenarios reflecting 
the effects of increasing variation at specific levels of the hierarchy. 
 
The full model estimated drug level comorbidity-treatment interaction effects without bias to 
the same extent as drug only models. MSE/RMSE values were similar in the full models and 
drug models in all cases, indicating that the degree of accuracy of the point estimates was at 
least equivalent. The largest difference in accuracy occurred in the “Trial level: high 
variation” scenario, where simulated trial-level effects were highly variable but drugs and 
drug classes relatively similar, when the full model was more precise by approximately 0.05 
SDs (RMSEdrug = 0.13; RMSEfull = 0.08). The models differed more markedly on the other 
two measures of performance, precision and coverage, for related reasons. The full model 
estimated drug level comorbidity-treatment interactions, on average, more precisely in all 
scenarios, and substantially so in most cases. This is the expected result of information 
sharing at the level of drug class. The relative precision of estimates from the two approaches 
is illustrated, as a function of drug class, in Figure 2. Precision gains related to use of the full 
model are most substantial for drugs with a limited number of trials (or only small trials; see 
sTable 1 for drug-specific details), and when drugs and drug classes are more similar and 
trial-level estimates more varied (e.g., “Trial level: high variation” scenario, middle panel). 
Precision in the full model was similar to or worse than in the drug model in all classes only 
when drug classes in the hierarchy were relatively dissimilar (e.g., “Class level: high 
variation” scenario, bottom-right panel).  
 
Coverage – the proportion of credible intervals including the “true” effect – was reduced in 
most instances in the full model, but this too is an expected feature of these models. It results 
from the combination of increased precision and shrinkage of extreme-for-class drug level 
effect estimates toward the class average. These features are illustrated in Figure 3, which 
shows the posterior distributions of effects of drugs in a specific class, as estimated in the full 
model (middle panel) and single drug models (lower panel), as they relate to the effect at the 
class level effect (top panel). Drug level effect distributions are shrunk (drawn towards the 
class level mean) and estimated more precisely in the full model when drugs in the hierarchy 
are sufficiently similar (e.g., “All levels: low variation” scenario, left-hand panels of Figure 
3). This means that the simulated effect for a given drug has more chance of falling outside 
the 95% credible intervals – but this is clearly desirable if the exchangeability assumption is 
met, as information from similar drugs has been used alongside the evidence available from 
trials of that drug to improve the estimate. In higher variation scenarios, the extent to which 
drug-level estimates are influenced by class-level information is flexible and proportionate to 
the homogeneity of effects within the class. In the example shown in Figure 3 in the “All 
levels: high variation” scenario (right-hand panels), shrinkage is minimal and only effects for 
gemigliptin and linagliptin are estimated more precisely in the full model, reflecting the fact 
that drugs and classes in this scenario are much less similar in terms of their subgroup effects. 
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Figure 4 illustrates the potentially clinically-meaningful impact of the increases in precision 
afforded by using the full model to estimate treatment interactions for related drugs in a 
hierarchy. It summarizes the proportion of all datasets in three main scenarios, in which a true 
drug-level subgroup effect of -0.10 or larger was able to be detected (i.e., with credible 
intervals not including zero) in i) both models; ii) the single drug model only; and iii) the full 
model only. For context, the panel on the right-hand side of the figure shows enrollment (i.e., 
N) for the largest trial per drug and aggregated across all trials of a drug. Effects in drugs with 
large trials and/or high aggregated enrollment were generally well-detected in both models, 
though a substantial proportion were only detected in the full model, especially in the “All 
levels: low variation” scenario. The drug-class level information-sharing in the full model 
was most beneficial for drugs with smaller/fewer trials (e.g., taspoglutide, and all drugs in 
classes A10BB and A10BX), where true effects were only detected in the full model, 
regardless of the extent of variation in the hierarchy.  
 
The results of sensitivity analyses for different rates of subgroup-defining comorbidity 




In this paper, we have demonstrated the feasibility of improving the estimation of treatment 
effects in sub-groups by using Bayesian hierarchical meta-analytic models that share 
information across related trials based on established classification ontologies. Our 
simulations, based on characteristics of real trials of non-insulin glucose lowering drugs for 
diabetes, show that partial-pooling of subgroup effects across classes of drugs is: a) feasible, 
given the amount of data that is theoretically available from trial sponsors; and b) effective at 
increasing the potential of sub-group effect estimation in the context of multimorbidity to 
influence clinical decision-making.  
 
In our simulations, Bayesian hierarchical models structured around the ATC ontology were 
unbiased, and compared favourably to standard meta-analytic approaches in terms of both 
their precision (estimates are more precise) and conservatism (extreme estimates at drug and 
trial levels are shrunk towards class means) for estimating subgroup effects. Both of these 
represent non-trivial improvements in the estimation of drug level subgroup effects, as lack of 
data from individual trials/standard meta-analyses has typically meant that estimates are often 
too imprecise to be clinically useful and concerns about ‘false positives’ are commonly 
expressed in the literature around subgroups (12,35). More precisely and reliably estimated 
subgroup effects have greater potential to be incorporated into guidelines and influence 
clinical decision-making. This is particularly important in the context of multimorbid patients 
– who represent more than 50% of individuals with any chronic condition – since current 
guidelines lack specific trial-based recommendations for the treatment of these individuals. 
(2) 
 
The core features of the model we have outlined will not be novel to anyone familiar with 
Bayesian hierarchical modelling, and with concepts such as shrinkage and exchangeability. 
Such readers will also likely be aware of the difficulties inherent in formalizing prior 
knowledge for use in such models. We propose that the use of existing ontologies – 
specifically, though not exclusively, of drugs – such as the ATC system, to structure 
hierarchical models for meta-analyses of trial data is a widely applicable solution to this 
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problem. In particular, we believe it to be immediately applicable to the challenge of 
estimating treatment effects in sub-groups of patients likely to be poorly represented in 
clinical trials, such as those with specific comorbidities. To illustrate the portability of this 
approach and make it easier for others to use the WHO-ATC classification system, we have 
developed an online application (Figure 5) that can be used to visualise hierarchical 
classifications for a large set of trials registered in the clinicaltrials.gov database with relevant 
metadata. The tool is available at https://ihwph-hehta.shinyapps.io/duk_example_app/. Users 
can select trial types, wider drug groupings, and conditions of interest to create a hierarchy 
that can then be visualised in different ways, and for which the constituent trials (complete 
with NCT ID numbers) can be exported as a table. The tool can also be used to visualize 
networks of trials including drug-drug comparisons, and the principles of the model evaluated 
in this paper can be straightforwardly extended to perform network meta-analyses including 
data from such trials. The R code for the diagram is also available 
https://github.com/dmcalli2/ctg_network_diagram. We anticipate continuing to update this 
tool using more recent data from clinicaltrials.gov. 
 
An advantage of using existing ontologies such as the ATC system,(23,24) is that they have 
already codified a considerable body of expert knowledge about similarities/differences 
between different drugs. However, such ontologies might be used with modifications in real 
settings, where a decision may be made to exclude a drug from a given class or exclude a 
class from the modelling. If, for example, a new class of drug was developed to address a 
perceived loss of efficacy in a particular subgroup (e.g., there is some evidence that certain 
classes of antiplatelet have a lower relative efficacy in women than in men (36)) it would not 
be appropriate to include other drug-classes with the same physiological action within the 
modelling. Future work could also explore the use of more complex relationships between 
drugs, by incorporating multiple ontologies.  
 
Limitations and assumptions 
The core assumption of this approach is that partially pooling interaction estimates across 
different drugs and, especially, across drug classes, is reasonable. When considering the 
validity of this assumption, it is worth taking into account the context for examining 
treatment effects in multimorbidity. In current practice, imprecise covariate-treatment 
interactions are typically either interpreted as evidence that no difference exists, or as 
evidence that the treatment is not efficacious in patients with the multimorbidity, often 
according to some unstated prior belief. More precise estimates can be obtained from large 
observational datasets; however, such analyses are subject to confounding by indication, 
which has been called an “intractable” problem of epidemiology.(9) Secondly, it is worth 
reiterating that the flexibility of these models means that hierarchical structures can be 
defined (and subsequently refined) based on expert opinion and empirical evidence regarding 
the validity of the core assumption for specific drug groupings. We anticipate that sensitivity 
analyses involving dropping specific classes and drugs from a hierarchy and comparing 
model fit will become a standard facet of this approach, but acknowledge that further work is 
needed to develop formal assumption testing measures for use with real data. In particular, it 
will be important to develop contingencies to ascertain when a drug level estimate is extreme 
because that drug truly behaves differently from others in its class, and hence when the 
shrinkage afforded by a Bayesian hierarchical model is undesirable. Nonetheless, it should be 
borne in mind that an implicit assumption of single-drug meta-analyses is that drugs with 
similar mechanisms of action are no more likely to have similar sub-group effects associated 
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with them than those operating via entirely different biological pathways. This assumption, 
were it to be made explicitly each time a single drug meta-analysis is performed, would likely 
be at least as debatable – if not more so – than the notion that related drugs may behave 
similarly to one another. 
 
The scale of IPD sharing that is required for network meta-analyses is clearly greater than 
that which is needed for individual-drug meta-analyses. However, an important facet of the 
models we propose is that their benefits can be propagated to future work. Once a large 
network meta-analysis has been run, the posterior distributions of effects at drug class and 
drug levels can be used as priors in subsequent analyses. Indeed, as more trial sponsors 
provide access to individual-level participant data for increasing numbers of trials (e.g., via 
ClinicalStudyDataRequest.com (37)) it is possible to envisage the eventual compiling of a 
database of ‘off-the-shelf’ priors for treatment-comorbidity interactions, which will enable 
health economists and others to more easily model the effect of treatments in people with 
multimorbidity. 
 
The simulations in our study are subject to certain limitations. First, although we restricted 
our simulation to the trial-level (rather than simulating IPD at the patient level) for 
computational reasons, we have only considered a situation where IPD are available for all 
trials. That is, IPD would almost certainly be needed from all trials to get results stratified by 
particular comorbidities. To more pragmatically reflect the likely availability of data from 
clinical trials, it would be useful to explore models designed to accommodate aggregate data 
alongside IPD. However, one issue that this would exacerbate is inconsistency of reporting of 
covariates. Given that covariate reporting is likely to be missing not-at-random, such models 
would need to account for bias or rely on specific covariate results being obtainable from 
sponsors (at an aggregate level) on request. Even within IPD, trials may not consistently 
record or define specific covariates, and the impact of these potential inconsistencies are not 
considered here. However, in the case of multimorbidity at least, we have recently 
demonstrated using IPD for over 100 trials shared by commercial sponsors, that it is possible 
to use generally well-recorded concomitant medication use data to facilitate the investigation 
of comorbidities.(8) Second, for simplicity we considered only a single comorbidity-
treatment interaction. It would be useful in future studies to consider multiple comorbidities. 
This would mean simulating the impact of between-trial information sharing in models where 
there is also within-trial sharing via, for example, the Dixon-Simon model, where a common 
prior is placed on all treatment-covariate interactions.(20) Third, there are a range of 
important possible scenarios that we do not address in the current simulation. These include 
scenarios (i) with a smaller overall interaction effect (including no interaction), (ii) where an 
interaction effect is differs in magnitude or direction across classes within a hierarchy, and 
scenarios where comorbidities are absent in some trials. These (and many others) are relevant 
and realistic considerations for the challenges that real data may pose. However, the 
multiplicities created by so many possible scenarios are a limitation for all simulation studies, 
and the drawing up of bounds on the simulated universe(s) to be investigated is an inherent 
part of study design. In future, potentially informed by the characteristics of real IPD where it 
is obtained, explorations of the capability of this approach to be informative in different 
scenarios would undoubtedly be beneficial. We have published our code which we or others 
could modify to examine these, and many other scenarios in future. 
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Summary and conclusions 
Determining treatment effectiveness in multimorbidity is a challenging problem. If we are 
willing to assume - informed by existing ontologies – a level of similarity between drugs, 
hierarchical models can be used to estimate comorbidity-treatment interactions with 
improved precision. This has the potential to support trial-based decision making for patients 
with multimorbidity. 
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Scenario   Single-drug model Full model 
Level(s) Variation Performance measure Estimate MCSE Estimate MCSE 
              
All Low  Bias 0.013 0.000 0.001 0.000 
All Low  MSE 0.003 0.000 0.003 0.000 
All Low  RMSE 0.058 0.000 0.056 0.000 
All Low  Rel. prec. ⁃ ⁃ 89.004 1.415 
All Low  Coverage 0.968 0.001 0.852 0.002 
All Medium  Bias 0.012 0.001 0.000 0.001 
All Medium  MSE 0.025 0.000 0.028 0.000 
All Medium  RMSE 0.159 0.001 0.166 0.001 
All Medium  Rel. prec. ⁃ ⁃ 13.212 0.435 
All Medium  Coverage 0.812 0.003 0.674 0.003 
All High  Bias 0.010 0.002 -0.003 0.002 
All High  MSE 0.069 0.001 0.076 0.001 
All High  RMSE 0.263 0.001 0.276 0.001 
All High  Rel. prec. ⁃ ⁃ 3.952 0.287 
All High  Coverage 0.759 0.003 0.624 0.003 
              
Trial Medium  Bias 0.012 0.001 0.000 0.000 
Trial Medium  MSE 0.008 0.000 0.005 0.000 
Trial Medium  RMSE 0.091 0.000 0.068 0.000 
Trial Medium  Rel. prec. ⁃ ⁃ 127.704 1.767 
Trial Medium  Coverage 0.958 0.001 0.897 0.002 
Trial High  Bias 0.014 0.001 0.001 0.000 
Trial High  MSE 0.017 0.000 0.006 0.000 
Trial High  RMSE 0.132 0.001 0.077 0.000 
Trial High  Rel. prec. ⁃ ⁃ 251.074 2.848 
Trial High  Coverage 0.959 0.001 0.944 0.001 
Drug Medium  Bias 0.013 0.001 0.001 0.001 
Drug Medium  MSE 0.004 0.000 0.007 0.000 
Drug Medium  RMSE 0.064 0.000 0.082 0.001 
Drug Medium  Rel. prec. ⁃ ⁃ 34.080 0.558 
Drug Medium  Coverage 0.968 0.001 0.902 0.002 
Drug High  Bias 0.013 0.001 0.000 0.001 
Drug High  MSE 0.006 0.000 0.008 0.000 
Drug High  RMSE 0.077 0.000 0.090 0.001 
Drug High  Rel. prec. ⁃ ⁃ 10.278 0.274 
Drug High  Coverage 0.968 0.001 0.911 0.002 
Class Medium  Bias 0.013 0.001 0.001 0.001 
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Class Medium  MSE 0.019 0.000 0.020 0.000 
Class Medium  RMSE 0.138 0.001 0.142 0.001 
Class Medium  Rel. prec. ⁃ ⁃ 3.648 0.443 
Class Medium  Coverage 0.785 0.003 0.542 0.003 
Class High  Bias 0.010 0.002 -0.003 0.002 
Class High  MSE 0.053 0.001 0.061 0.001 
Class High  RMSE 0.230 0.001 0.246 0.001 
Class High  Rel. prec. ⁃ ⁃ -10.158 0.283 
Class High  Coverage 0.676 0.003 0.380 0.003 
              
 
 
Table 1.  Summary of performance measures for full and single drug only models across all simulated 
datasets for different scenarios 
Note – See Data generation procedure in Methods for full definition of scenarios; MSE 
=mean squared error; RMSE=root mean squared error; Rel. precision = % change in 
precision for full vs. drug model; Coverage = proportion of 95% credible intervals 
containing true effect; MCSE = Monte Carlo standard errors; RMSE estimates and 
corresponding MCSEs are not calculated by default in the rsimsum package and so are 
instead derived, with the MCSE approximated using the delta method, i.e.: 
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Figure 1. Schematic overview of the proposed and comparator approaches in the current simulation 
study – shown for a subset of drugs within two classes the A10B ATC4 class used as the basis for the 
simulation 
Figure 2. Summary of relative precision of drug level comorbidity-treatment interaction effects in full 
vs. single drug model as a function of drug class 
Figure 3.  Posterior densities estimated for interaction effects at the drug class (top panel) and drug 
level (middle panel) from the full model and at the drug level (bottom panel) from single drug models 
for drugs in the A10BH class in a single randomly-selected dataset in the All levels: low variation and 
All levels: high variation scenarios, illustrating properties of shrinkage at the drug level in the full 
model 
Figure 4.  Illustration of the impact of increased precision in the full model: summarising the 
proportion of all datasets with “true” effects in the three main scenarios in which credible intervals for 
the interaction effect estimate for each drug excluded zero (i.e., no interaction) in i) both models; ii) 
the single drug model only; and iii) the full model only, alongside enrollment information   
Figure 5.  Introduction to an online tool for drawing network hierarchies of trials nested within drugs 





Figure 1. Schematic overview of the proposed and comparator approaches in the current simulation study – shown for a subset of drugs 
within two classes the A10B ATC4 class used as the basis for the simulation 
Note – only a subset of the hierarchy is shown in the interests of managing space constraints; in the study the full hierarchical meta-analytic model is 
applied to a network incorporating all A10B drugs, and single drug meta-analyses are similarly run for all drugs in the network 
 
Figure 2. Summary of relative precision of drug level comorbidity-treatment interaction effects in full 
vs. single drug model as a function of drug class 
Note – error bars show Monte-Carlo standard errors; information on the number and size of trials for each 
drug class is found in sTable 1; in contrast to the values in Table 1 where relative precision is always 
displayed as % change in precision for the full model relative to the drug model, here the “comparator 





Figure 3.  Posterior densities estimated for interaction effects at the drug class (top panel) and drug level (middle panel) from the full model and at the drug 
level (bottom panel) from single drug models for drugs in the A10BH class in a single randomly-selected dataset in the All levels: low variation and All levels: 




Figure 4.  Illustration of the impact of increased precision in the full model: summarising the 
proportion of all datasets with “true” effects in the three main scenarios in which credible intervals for 
the interaction effect estimate for each drug excluded zero (i.e., no interaction) in i) both models; ii) 




















Figure 5.  Introduction to an online tool for drawing network hierarchies of trials nested within drugs and drug 
WHO-ATC drug classes ascertained based on clinical trials with relevant metadata on clinicaltrials.gov 
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sTable 1. Classification of drugs from the diabetes trial-set into classes based on WHO-ATC-5 
sTable 2. Example dataset from simulation (abbreviated to 20 rows) 
sTable 3. Summary of performance measures for full and single drug only models across all simulated datasets for 
different scenarios – LOW SIMULATED COMORBIDITY PREVALENCE (10%) 
sTable 4 Summary of performance measures for full and single drug only models across all simulated datasets for 
different scenarios – HIGH SIMULATED COMORBIDITY PREVALENCE (50%) 
 
 
sFigure 1 Summary of relative precision of drug level comorbidity-treatment interaction effects in full vs. single 
drug model as a function of drug class– LOW SIMULATED COMORBIDITY PREVALENCE (10%) 
sFigure 2  Summary of relative precision of drug level comorbidity-treatment interaction effects in full vs. single 
drug model as a function of drug class– HIGH SIMULATED COMORBIDITY PREVALENCE (50%) 
sFigure 3 Illustration of the impact of increased precision in the full model: summarising the proportion of all 
datasets with “true” effects in the three main scenarios in which credible intervals for the interaction effect 
estimate for each drug excluded zero (i.e., no interaction) in i) both models; ii) the single drug model only; 
and iii) the full model only, alongside enrollment information  – LOW SIMULATED COMORBIDITY 
PREVALENCE (10%) 
sFigure 4 Illustration of the impact of increased precision in the full model: summarising the proportion of all 
datasets with “true” effects in the three main scenarios in which credible intervals for the interaction effect 
estimate for each drug excluded zero (i.e., no interaction) in i) both models; ii) the single drug model only; 






Each set of trials was organised into a hierarchy based on the biological mechanism of action of the drugs 
under study. For the diabetes trial-set, the WHO-ATC-5 level grouping of included drugs was closely 
reflective of the mechanism of action, so this was used as a node in the hierarchy. As a result, diabetes trials 
were nested within drugs, drugs were nested within WHO-ATC-5 drug classes, and drug classes were nested 
within the wider drug grouping (the WHO-ATC-4 level code A10B). The full network diagram for the 
diabetes trials can be viewed online here: https://ihwph-hehta.shinyapps.io/duk_example_app/. The 




In order to simulate interaction effects and their precision at the trial-level (but without simulating IPD in 
full), four groups per trial were defined overall: two for each arm (those with and without the comorbidity). 
We assumed one-to-one randomisation within a two-group parallel design, and that the comorbidity was 
equally common in the intervention and control arms. The precision of the comorbidity-treatment interaction 
estimate was approximated as the inverse of the sum of the standard errors-squared for each of the four 
groups, where the standard error for each group was estimated as the standard deviation for the standardised 
outcome (by definition one), divided by the square root of the number of participants in that group. The N-
per-group was calculated by combining the trial-specific enrolment (as recorded in clinicaltrials.gov) and the 
specified prevalence for the comorbidity (see below).   
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Supplementary tables  
Drug WHO-ATC level 5 code ATC-5 class description ATC-7 code N trials Total N participants 
metformin A10BA biguanide A10BA02 4 1220 
glipizide A10BB A10BB Sulfonylureas A10BB07 1 700 
glimepiride A10BB A10BB Sulfonylureas A10BB12 2 618 
rivoglitazone A10BG thiazolidinedione A10BG_2 1 910 
rosiglitazone A10BG thiazolidinedione A10BG02 4 2134 
pioglitazone A10BG thiazolidinedione A10BG03 2 948 
sitagliptin A10BH dpp-4 inhibitor A10BH01 20 23766 
vildagliptin A10BH dpp-4 inhibitor A10BH02 16 11158 
saxagliptin A10BH dpp-4 inhibitor A10BH03 11 24404 
alogliptin A10BH dpp-4 inhibitor A10BH04 5 6944 
linagliptin A10BH dpp-4 inhibitor A10BH05 13 14452 
gemigliptin A10BH dpp-4 inhibitor A10BH06 1 288 
taspoglutide A10BJ glp-1 receptor agonist A10BJ_3 1 332 
exenatide A10BJ glp-1 receptor agonist A10BJ01 7 20402 
liraglutide A10BJ glp-1 receptor agonist A10BJ02 8 12534 
lixisenatide A10BJ glp-1 receptor agonist A10BJ03 13 6058 
albiglutide A10BJ glp-1 receptor agonist A10BJ04 6 11142 
dulaglutide A10BJ glp-1 receptor agonist A10BJ05 4 10504 
dapagliflozin A10BK A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors A10BK01 22 32198 
canagliflozin A10BK A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors A10BK02 9 15724 
empagliflozin A10BK A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors A10BK03 8 8390 
repaglinide A10BX glinide A10BX02 1 324 
nateglinide A10BX glinide A10BX03 1 4652 
mitiglinide A10BX glinide A10BX08 1 244 


























NCT00819741 A10BA metformin 216 0.08 0.19 
NCT01512979 A10BA metformin 158 0.07 0.23 
NCT01545388 A10BA metformin 112 0.07 0.27 
NCT02068443 A10BA metformin 124 0.13 0.25 
NCT00131664 A10BB glimepiride 130 -0.14 0.25 
NCT01459809 A10BB glimepiride 179 -0.11 0.21 
NCT00086515 A10BB glipizide 350 -0.19 0.15 
NCT00094757 A10BG pioglitazone 173 -0.26 0.22 
NCT00220961 A10BG pioglitazone 301 -0.23 0.16 
NCT00484198 A10BG rivoglitazone 455 -0.10 0.13 
NCT00241605 A10BG rosiglitazone 300 0.05 0.16 
NCT00359112 A10BG rosiglitazone 272 0.03 0.17 
NCT00386100 A10BG rosiglitazone 344 -0.03 0.15 
NCT00499707 A10BG rosiglitazone 151 -0.05 0.23 
NCT00286494 A10BH alogliptin 164 -0.19 0.22 
NCT00432276 A10BH alogliptin 401 -0.34 0.14 
NCT00968708 A10BH alogliptin 2690 -0.20 0.05 
NCT01318070 A10BH alogliptin 113 -0.24 0.27 
NCT01318083 A10BH alogliptin 104 -0.26 0.28 
NCT01787396 A10BH gemigliptin 144 -0.10 0.24 
… 
     
 
sTable 2. Example dataset from simulation (abbreviated to 20 rows) 
Notes: 1 The standard error of the interaction effect estimate for each trial was derived by assuming a 
SD of 1 for the main effect in a trial, and using the number of participants per group in each trial to 
calculate standard errors for subgroups with and without a hypothetical comorbidity (prevalence set at 
0.2), which were combined to give the overall variance of the interaction estimate  
 5 
Scenario   Single-drug model Full model 
Level(s) Variation Performance measure Estimate MCSE Estimate MCSE 
              
All Low  Bias 0.013 0.000 0.001 0.000 
All Low  MSE 0.003 0.000 0.003 0.000 
All Low  RMSE 0.058 0.000 0.056 0.000 
All Low  Rel. prec. ⁃ ⁃ 122.727 1.868 
All Low  Coverage 0.989 0.001 0.889 0.002 
All Medium  Bias 0.013 0.001 0.000 0.001 
All Medium  MSE 0.025 0.000 0.028 0.000 
All Medium  RMSE 0.160 0.001 0.167 0.001 
All Medium  Rel. prec. ⁃ ⁃ 20.311 0.543 
All Medium  Coverage 0.855 0.002 0.719 0.003 
All High  Bias 0.010 0.002 -0.003 0.002 
All High  MSE 0.069 0.001 0.077 0.001 
All High  RMSE 0.263 0.001 0.277 0.001 
All High  Rel. prec. ⁃ ⁃ 7.028 0.345 
All High  Coverage 0.783 0.003 0.651 0.003 
      
    
Trial Medium  Bias 0.012 0.001 0.000 0.000 
Trial Medium  MSE 0.009 0.000 0.005 0.000 
Trial Medium  RMSE 0.093 0.000 0.069 0.000 
Trial Medium  Rel. prec. ⁃ ⁃ 134.132 1.922 
Trial Medium  Coverage 0.977 0.001 0.918 0.002 
Trial High  Bias 0.014 0.001 0.002 0.001 
Trial High  MSE 0.018 0.000 0.007 0.000 
Trial High  RMSE 0.134 0.001 0.081 0.000 
Trial High  Rel. prec. ⁃ ⁃ 221.363 2.696 
Trial High  Coverage 0.968 0.001 0.950 0.001 
Drug Medium  Bias 0.013 0.001 0.001 0.001 
Drug Medium  MSE 0.004 0.000 0.008 0.000 
Drug Medium  RMSE 0.065 0.000 0.090 0.001 
Drug Medium  Rel. prec. ⁃ ⁃ 56.857 0.797 
Drug Medium  Coverage 0.989 0.001 0.938 0.002 
Drug High  Bias 0.013 0.001 0.000 0.001 
Drug High  MSE 0.006 0.000 0.011 0.000 
Drug High  RMSE 0.077 0.000 0.107 0.001 
Drug High  Rel. prec. ⁃ ⁃ 22.996 0.399 
Drug High  Coverage 0.989 0.001 0.953 0.001 
Class Medium  Bias 0.014 0.001 0.001 0.001 
Class Medium  MSE 0.019 0.000 0.019 0.000 
Class Medium  RMSE 0.138 0.001 0.138 0.001 
Class Medium  Rel. prec. ⁃ ⁃ 12.471 0.544 
Class Medium  Coverage 0.846 0.002 0.606 0.003 
 6 
Class High  Bias 0.010 0.001 -0.003 0.002 
Class High  MSE 0.052 0.001 0.058 0.001 
Class High  RMSE 0.229 0.001 0.241 0.001 
Class High  Rel. prec. ⁃ ⁃ -6.145 0.322 
Class High  Coverage 0.737 0.003 0.447 0.003 
              
 
sTable 3. Summary of performance measures for full and single drug only models across all simulated 
datasets for different scenarios – LOW SIMULATED COMORBIDITY PREVALENCE (10%) 
Note – See Data generation procedure in Methods for full definition of scenarios; MSE =mean squared error; 
RMSE=root mean squared error; Rel. precision = % change in precision for full vs. drug model; Coverage = 
proportion of 95% credible intervals containing true effect; MCSE = Monte Carlo standard errors; RMSE 
estimates and corresponding MCSEs are not calculated by default in the rsimsum package and so are instead 
derived, with the MCSE approximated using the delta method, i.e.: 
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Scenario   Single-drug model Full model 
Level(s) Variation Performance measure Estimate MCSE Estimate MCSE 
              
All Low  Bias 0.013 0.000 0.001 0.000 
All Low  MSE 0.003 0.000 0.003 0.000 
All Low  RMSE 0.057 0.000 0.056 0.000 
All Low  Rel. prec. ⁃ ⁃ 65.898 1.127 
All Low  Coverage 0.943 0.001 0.821 0.002 
All Medium  Bias 0.012 0.001 0.000 0.001 
All Medium  MSE 0.025 0.000 0.027 0.000 
All Medium  RMSE 0.159 0.001 0.165 0.001 
All Medium  Rel. prec. ⁃ ⁃ 9.408 0.370 
All Medium  Coverage 0.783 0.003 0.647 0.003 
All High  Bias 0.010 0.002 -0.003 0.002 
All High  MSE 0.069 0.001 0.076 0.001 
All High  RMSE 0.263 0.001 0.276 0.001 
All High  Rel. prec. ⁃ ⁃ 2.398 0.261 
All High  Coverage 0.748 0.003 0.609 0.003 
      
    
Trial Medium  Bias 0.012 0.001 0.000 0.000 
Trial Medium  MSE 0.008 0.000 0.004 0.000 
Trial Medium  RMSE 0.090 0.000 0.067 0.000 
Trial Medium  Rel. prec. ⁃ ⁃ 129.466 1.703 
Trial Medium  Coverage 0.944 0.001 0.884 0.002 
Trial High  Bias 0.013 0.001 0.001 0.000 
Trial High  MSE 0.017 0.000 0.006 0.000 
Trial High  RMSE 0.131 0.001 0.075 0.000 
Trial High  Rel. prec. ⁃ ⁃ 263.698 2.887 
Trial High  Coverage 0.955 0.001 0.942 0.002 
Drug Medium  Bias 0.013 0.001 0.001 0.001 
Drug Medium  MSE 0.004 0.000 0.006 0.000 
Drug Medium  RMSE 0.064 0.000 0.076 0.000 
Drug Medium  Rel. prec. ⁃ ⁃ 21.332 0.425 
Drug Medium  Coverage 0.943 0.001 0.860 0.002 
Drug High  Bias 0.012 0.002 0.000 0.001 
Drug High  MSE 0.006 0.000 0.006 0.000 
Drug High  RMSE 0.076 0.000 0.080 0.001 
Drug High  Rel. prec. ⁃ ⁃ 2.542 0.215 
Drug High  Coverage 0.943 0.001 0.867 0.002 
Class Medium  Bias 0.013 0.001 0.001 0.001 
Class Medium  MSE 0.019 0.000 0.021 0.000 
Class Medium  RMSE 0.139 0.001 0.145 0.001 
Class Medium  Rel. prec. ⁃ ⁃ -1.838 0.384 
Class Medium  Coverage 0.739 0.003 0.494 0.003 
 8 
Class High  Bias 0.010 0.002 -0.003 0.002 
Class High  MSE 0.053 0.001 0.062 0.001 
Class High  RMSE 0.230 0.001 0.249 0.001 
Class High  Rel. prec. ⁃ ⁃ -12.440 0.263 
Class High  Coverage 0.635 0.003 0.333 0.003 
              
 
sTable 4 Summary of performance measures for full and single drug only models across all simulated 
datasets for different scenarios – HIGH SIMULATED COMORBIDITY PREVALENCE (50%) 
Note – See Data generation procedure in Methods for full definition of scenarios; MSE =mean squared error; 
RMSE=root mean squared error; Rel. precision = % change in precision for full vs. drug model; Coverage = 
proportion of 95% credible intervals containing true effect; MCSE = Monte Carlo standard errors; RMSE 
estimates and corresponding MCSEs are not calculated by default in the rsimsum package and so are instead 
derived, with the MCSE approximated using the delta method, i.e.: 































sFigure 1 Summary of relative precision of drug level comorbidity-
treatment interaction effects in full vs. single drug model as a function of 
drug class– LOW SIMULATED COMORBIDITY PREVALENCE 
(10%) 
Note – error bars show Monte-Carlo standard errors; information on the 





sFigure 2  Summary of relative precision of drug level comorbidity-treatment 
interaction effects in full vs. single drug model as a function of drug class– HIGH 
SIMULATED COMORBIDITY PREVALENCE (50%) 
Note – error bars show Monte-Carlo standard errors; information on the number and 




sFigure 3 Illustration of the impact of increased precision in the full model: summarising the 
proportion of all datasets with “true” effects in the three main scenarios in which credible intervals 
for the interaction effect estimate for each drug excluded zero (i.e., no interaction) in i) both models; 
ii) the single drug model only; and iii) the full model only, alongside enrollment information  – 




sFigure 4 Illustration of the impact of increased precision in the full model: summarising 
the proportion of all datasets with “true” effects in the three main scenarios in which 
credible intervals for the interaction effect estimate for each drug excluded zero (i.e., no 
interaction) in i) both models; ii) the single drug model only; and iii) the full model only, 
alongside enrollment information – HIGH SIMULATED COMORBIDITY 
PREVALENCE (50%) 
